1	The effects of the infarct volume on cytokines and			
2	immune status in patients with acute ischemic stroke			
3	Short title: The immune status of patients with acute cerebral infarction is			
4	related to the infarct volume			
5 6 7	Author:Xingqi Su <sup>1</sup> , Lingmin Zhao1¶, Di Ma <sup>1*</sup> ,Jiulin You <sup>1</sup> ,LiangShu Feng <sup>1</sup> ,jing wang <sup>1</sup> ,YuLei Hao <sup>1</sup> ,XinYu Wang <sup>1</sup> ,JiaChun Feng <sup>1</sup>			
8				
9	<sup>1</sup> Affiliation:Bethune First Hospital, Jilin University, Changchun, China			
10	* Corresponding author:Di Ma,LiJuan Wang			
11	Email:			
12	madi2017@jlu.edu.cn(M.D)			
13	wanglj66@jlu.edu.cn(W.Lj)			
14				

#### Abstract 15

**Objective:** To investigate and analyze the effects of the infarct volume on cytokines 16 and immune status in patients with acute ischemic stroke. Methods: Patients with acute 17 ischemic stroke that presented within 72 h of onset from October 2017 to October 2019 18 were enrolled. Patients with severe cerebral infarction (large-area cerebral infarction) 19 (n=34) were enrolled and categorized as group A; Additionally, 33 patients with non-20 large-area cerebral infarction with matching baseline characteristics (sex and age) to 21 group A were included in group B. We measured IL-2, IL-4, IL-6, IL-10, IL-17A, TNF-22  $\alpha$ , and IFN- $\gamma$  levels in serum using a cytometric bead array. In addition, we compared 23 24 the absolute value of lymphocytes (LYM#), lymphocyte percentage (LYM%), NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25	neutrophil/lymphocyte ratio (NLR), cytokine levels, and immune status indicators
26	(IFN- $\gamma$ IL-4 ratio, TNF- $\alpha$ /IL-4 ratio, and TNF- $\alpha$ /IL-10 ratio) between groups A and B,
27	and evaluated the effect of infarct size on inflammatory factors and immune status.
28	Results: Compared with group B, the LYM# and LYM% in group A were significantly
29	lower, and the NLR and cytokines (IL-2, IL-4, IL-6, IL-10, IL-17A, TNF- $\alpha$ , and IFN-
30	$\gamma$ ) levels were significantly higher. TNF- $\alpha$ /IL-4 ratio was significantly lower, and the
31	IFN- $\gamma$ /IL-4 ratio (P=0.09) and TNF- $\alpha$ /IL-10 ratio (P=0.146) in group A demonstrated a
32	decreasing trend although not significant. Conclusions: The immune status of patients
33	with acute cerebral infarction is related to the infarct volume; patients with large-area
34	cerebral infarction are more likely to develop immunosuppression.

35

### 36 Key words

Acute cerebral infarction, immunity, inflammation, cytokines, inflammatorycells,infarct volume

39

## 40 1. Introduction

According to the all-cause mortality statistics of the World Health Organization (WHO), stroke is the second leading cause of death globally, accounting for 87%[1], and its high disability rate significantly increases the social burden. Because immunity is crucial in cerebral infarction and, in turn, is regulated by it, the immune mechanism has become a target that may benefit clinical treatment and has attracted increasing interest from researchers.

47 Notably, immunity is crucial in the occurrence, progression, and outcome of48 ischemic stroke. The basic pathology of atherosclerotic cerebral infarction is

atherosclerosis. Various immune cells, including lymphocytes and mononuclear 49 macrophages, are involved in the formation of atherosclerotic plaques and the rupture 50 of unstable plaques[2,3], an important cause of atherosclerotic cerebral infarction[4]. 51 Immunity contributes to the pathogenesis of cerebral infarction and affects 52 prognosis[5-8]. After local cerebral infarction, astrocytes and microglia, which are 53 54 involved in the release of cytokines and chemokines[9], are rapidly activated, attract 55 immune cells from the peripheral circulation to the ischemic area, and participate in inflammatory damage to the brain tissue[10]. In addition, in the recovery from chronic 56 57 cerebral infarction, the immune status affects the brain tissue microenvironment, regulates neurogenesis[11,12] and angiogenesis[13], and affects the autoimmune 58 response to brain tissue antigens after stroke, mediating the long-term prognosis[5,6]. 59 Notably, as a stress event, ischemic stroke regulates systemic immunity through the 60 sympathetic nervous system and the hypothalamus-pituitary-adrenal axis, which is an 61 62 important mechanism of post-stroke immunosuppression, leading to increase mortality of patients with acute cerebral infarction [7,8,16-19]. We know that the size of different 63 affects infarcts also the treatment and prognosis of acute ischemic 64 stroke.(PMED: 28665171)In this study, we investigate and analyze the effects of the 65 infarct volume on cytokines and immune status in patients with acute ischemic 66 stroke. This enables the clinicians to make informed decisions in selecting 67 immunotherapy approaches and tailor rehabilitation strategies to optimize patient 68 outcomes by considering different infarct sizes. 69

70

## 71 2. Materials and methods

### 72 2.1 Research objects and samples

73 Inclusion criteria:

74	1. Patients with acute ischemic stroke presenting with an onset time of $\leq$ 72 h in				
75	the Department of Neurology of the First Hospital of Jilin				
76	University(Changchun, China) from October 2017 to October 2019.				
77	2. Patients who voluntarily participated in the study.				
78	3. Patients aged 18-80 years old, regardless of sex.				
79	Exclusion criteria:				
80	1. Intracranial artery dissection, aneurysm, vascular inflammatory diseases,				
81	vascular malformations, and other neurological diseases.				
82	2. Patients who have undergone thrombolysis or thrombectomy.				
83	3. Patients with or suspected cerebral embolism.				
84	4. Abnormal liver and kidney function; AST or ALT 3 times higher than the upper				
85	limit of normal value; creatinine clearance rate of <0.6 mL/s; blood creatinine				
86	level >265 $\mu$ mol/L.				
87	5. Patients with autoimmune diseases, who have received immunotherapy, or with				
88	malignant tumors.				
89	6. Patients with severe trauma or have undergone major surgery recently.				
90	Sample collection:				
91	Peripheral blood (2-3 mL) of the patients were collected immediately after				
92	admission using a coagulation blood collection tube. After centrifugation (4 °C, 3000				
93	r/min, 5 min), the supernatant (serum samples) was collected and cryopreserved at -				
94	80 °C.				
95	2.2 Reagents and equipment:				

BD FACS Calibur flow cytometer (BD Company, USA); low-temperature highspeed centrifuge (Heraeus Sepaeeh, Germany); low-temperature refrigerator (Haier

98 Company, Qingdao, China); BD<sup>™</sup> Cytometric Bead Array (CBA) human
99 Th1/Th2/Th17 kit (BD Company, USA); BD<sup>™</sup> Cytometric Bead Array (CBA) Human
100 Soluble Protein Master Buffer kit, (BD Company, USA).

### 101 2.3 Determination of cytokines in serum samples by CBA

### 102 method

103 The BD<sup>TM</sup> Cytometric Bead Array (CBA) human Th1/Th2/Th17 kit was used to 104 determine the cytokine (IL-2, IL-6, IL-4, IL-10, IL-17A, IFN- $\gamma$ , TNF- $\alpha$ ) levels in each 105 serum sample according to the manufacturer's instructions.

### **106 2.4 Experimental group**

A total of 67 patients presenting with an onset time of 72 h were included in this study;patients with large-area cerebral infarction were included in the large-area cerebral infarction group and categorized as group A. A total of 34 patients, including patients with anterior circulation infarction and posterior circulation infarction, were included. For anterior circulation infarction, the maximum diameter of the infarct was >3 cm (25 participants), and regarding posterior circulation infarction, the maximum infarction cross-section was >1/3 of the brainstem (9 participants).

Additionally, 33 patients with non-large-area cerebral infarction with matching sex and age with Group A were included in the non-large-area cerebral infarction group and categorized as Group B, including patients with anterior circulation infarction and posterior circulation infarction. For anterior circulation infarctions, the largest infarct diameter was <3 cm (27 participants), and for posterior circulation infarctions, the largest brainstem infarct area was <1/3 of the cross-sectional area (6 participants).

### 120 **2.5 Statistical analysis and graph**

121 Statistical analysis was performed using IBM SPSS Statistics version 25.0 (IBM

Corp., Armonk, N.Y., USA), and GraphPad Prism version 7 (GraphPad Software, Inc., 122 La Jolla, CA, USA) was used for graphing. The counted data were presented as the 123 number of cases (n) and percentages (%). Measurement data with normal distribution 124 are presented as  $\overline{x} \pm s$  and measurement data that are not normally distributed are 125 presented as the median and quartile M (Q25–Q75). For counting data, the Chi-square 126 test ( $\kappa$ 2 test) was used to compare groups. For the comparison between the two groups 127 of measurement data, the t-test was used for normally distributed data, and the 128 nonparametric rank-sum test (Mann-Whitney U test) was used for non-normal 129 distribution. For the comparison between the three groups of measurement data, a one-130 way analysis of variance (ANOVA) was used for the normal distribution, and the 131 variance was uniform. The LSD-t test was used for the pairwise comparison of the mean 132 between the groups. 133

The groups showed statistically significant differences, with a P-value of <0.05 indicating statistical significance; for pairwise comparison of the mean between the groups, the statistical difference was based on the unadjusted P-value <0.017 and the adjusted P-value <0.05.

### 138 **3. Results**

We compared the expression levels of various cytokines, including IL-2, IL-4, IL-6, IL-10, and IL17A, in the large-area infarction group (group A) and the non-largearea infarction group (group B) based on the same baseline level. Furthermore, we compared the absolute lymphocyte value (LYM#), lymphocyte ratio lymphocyte percentage (LYM%), neutrophil/lymphocyte ratio (NLR), IFN-γ/IL-4 ratio, TNF-α/IL-4 ratio, and TNF-α/IL-10 ratio between groups A and B.

The results indicated the following: (1) The cytokine levels in group A were significantly higher than in group B, as shown in Table 2 and Fig 1. These differences

were considered statistically significant; P< 0.05. (2) Group A exhibited significantly lower LYM# and LYM% than group B, and the NLR was significantly higher. These findings are presented in Table 3 and Fig 2 and showed statistically significant differences. (3) The TNF- $\alpha$ /IL-4 ratio in group A was significantly lower than in group B, which showed a statistically significant difference. The TNF- $\alpha$ /IL-10 ratio and IFN- $\gamma$ /IL-4 ratio in group A demonstrated a decreasing trend but showed no statistically significant differences (Table 4 and Fig 3).

- 154
- 155

Table 1. Baseline data between patients in group A and group B.

Baseline	Group A	Group B	P-value
Sex, Male (n, %)	19 (55.88%)	24 (72.7%)	0.151
Female (n, %)	15 (44.12%)	9 (27.3%)	
Hypertension (n, %)	23 (67.65%)	26 (78.79%)	0.304
Diabetes (n, %)	10 (29.42%)	10 (30.30%)	0.936
Smoking history (n, %)	14 (41.17%)	13 (39.39%)	0.882
Age (years)	63.5 (57–69)	62.5 (56.25-69)	0.768
LDL-C (mmol/L)	3.06 (2.72–4.34)	2.9 (2.29–3.86)	0.075
Hcy (µmol/L)	14.45 (10.93–19.65)	15.3 (13.4–20.8)	0.166
Fasting blood	5.84 (5.23-7.93)	5.71 (4.96-6.61)	0.349
glucose (mmol/L)			
NIHSS score	13 (11–16.25)	4 (3-8)	0.000

156

157



 Table 2. Serum cytokine levels of patients of group A and group B.

Cytokine level	Group A	Group B	U-value	P-value
IL-6 (pg/mL)	32.35 (9.69–56.60)	9.81 (3.09–28.60)	320.00	0.003
IL-4 (pg/mL)	4.02 (3.45-4.76)	0.58 (0.31–0.80)	27.00	0.000
IL-2 (pg/mL)	1.96 (1.75–2.19)	0.55 (0.32–0.98)	84.50	0.000
IL-17A (pg/mL)	8.15 (6.30–9.66)	3.25 (1.37–5.08)	142.00	0.000
IFN-γ (pg/mL)	2.58 (2.30-2.99)	0.61 (0.22–0.95)	13.00	0.000
TNFα (pg/mL)	2.63 (2.23–3.15)	1.71 (0.80–2.82)	284.00	0.001
IL-10 (pg/mL)	3.43 (2.66–4.52)	1.31 (0.89–2.46)	169.00	0.000

Mann-Whitney U test was used. The cytokine levels in group A were significantly 

### Fig 1. Serum cytokine levels of groups A and group B patients.

### Table 3. LYM#, LYM%, and NLR between group A and group B.

Indicators	Group A	Group B	U-value	P-value
LYM# (^10 <sup>9</sup> )	1.41 (1.05–1.79)	1.76 (1.43–2.35)	324.50	0.003
LYM%	0.14 (0.08–0.22)	0.26 (0.21–0.33)	214.00	0.000
NLR	5.27 (3.26–10.79)	2.61 (1.73–3.36)	204.00	0.000

Mann–Whitney U test was used. The LYM# and LYM% of the large-area group (group 

A) were significantly lower than those of the non-large-area group (group B), while the 

NLR of group A was significantly higher than that of group B. 

higher than in group B. 

#### 172 Fig 2. LYM#, LYM%, NLR of group A and group B.

174

175

### Table 4. Indicators of immune status of patients in group A and group B.

Indicators	Group A	Group B	U-value	P-value
TNF-α/IL-4	0.69 (0.54–0.83)	2.50 (1.62–5.99)	137.00	0.000
TNF-α/IL-10	0.80 (0.53–1.12)	1.05 (0.53-3.06)	445.00	0.146
IFN-y/IL-4	0.66 (0.52–0.82)	1.07 (0.40-2.06)	426.00	0.090

Mann–Whitney U test was used. The TNF- $\alpha$ /IL-4 ratio in group A was significantly 176

lower than in group B; the TNF- $\alpha$ /IL-10 and IFN- $\gamma$ /IL-4 ratios in group A showed a 177 downward trend. 178

179

Fig 3. Immune status of patients in group A and group B. 180

\*\* P<0.01. 181

182

### 4. Discussion 183

Ischemic stroke is a common cerebrovascular disease; it causes irreversible brain 184 tissue damage. The complex pathological mechanism includes excitatory glutamate 185 toxicity, calcium overload, oxidative stress, and inflammatory damage. 186

Inflammatory reaction is crucial in brain tissue injury following infarction. The 187 immune state regulates local pathophysiological changes and significantly affects the 188 outcome of ischemic tissues. The proinflammatory state aggravates local injury; 189 however, the anti-inflammatory state protects the local brain tissue, promotes the 190 removal of necrotic cells, and prevents further damage. Inflammation of the central 191 nervous system and peripheral systemic immunity are closely linked and reflect the 192

delicate and ingenious integrity of the human body. For example, the blood-brain
barrier (BBB) is compromised after cerebral infarction and peripheral immune cells
invade the brain tissue. The Th cells that invade the central nervous system secrete
several cytokines and interact with microglia to initiate microglial polarization [14,15];
this affects the degree and outcome of the local brain tissue damage.

The relationship between the nervous and immune systems is such that the immune system affects the pathophysiological changes of cerebral infarction and is, in turn, affected by cerebral infarction events, such as immunosuppression after stroke. The underlying mechanism is not fully understood.Post-stroke immunosuppression is a self-protective mechanism for suppressing central inflammation; however, it alters peripheral immune status and further affects the prognosis in patients with acute cerebral infarction[7–8].

Considering the role of immune factors in the course of cerebral infarction, 205 investigating the immune mechanisms has increasingly attracted the interest of 206 researchers. The body's immunity is affected by several factors, and some related 207 factors can be controlled artificially; therefore, the immune mechanism may be a 208 potential clinical treatment target. In this study, we evaluated the levels of various 209 cytokines, including IL-2, IL-6, TNF- $\alpha$ , IFN- $\gamma$ , IL-4, IL-10, and IL-17A in patients 210 presenting with acute cerebral infarction within 72 h of onset, and calculated the INF-211  $\gamma$ /IL-4, TNF- $\alpha$ /IL-4, and TNF- $\alpha$ /IL-10 ratios. The IFN- $\gamma$ /IL-4 ratio indicates the balance 212 between the subpopulations of helper T cells, reflecting the relative function between 213 the Th1 and Th2 subpopulations. IFN- $\gamma$  is an essential proinflammatory cytokine 214 secreted by Th1-type cells, while IL-4 is a relatively specific cytokine of Th2-type cells 215 and exerts an anti-inflammatory effect. The initial Th cells, Th0 cells, are regulated by 216 several factors and differentiated into subpopulations. The most significant factor is the 217

type and level of cytokines and the balance between each cytokine[20]. Therefore, the 218 IFN-v/IL-4 ratio is of great significance. Furthermore, the mononuclear macrophage 219 system is divided into M1- and M2-type responses and is regulated by the Th1/Th2 220 immune status. Proinflammatory M1-type macrophages are polarized by binding to 221 lipopolysaccharide (LPS) or Th1-type cytokines (such as IFN- $\gamma$ ), producing 222 proinflammatory cytokines including IL-1 $\beta$ , IL- 23, TNF- $\alpha$ ; anti-inflammatory M2 223 macrophages are polarized by Th2-related cytokines, such as IL-4 and IL-13, and 224 secrete anti-inflammatory cytokines such as IL-10 and TGF-B[21], promoting tissue 225 226 healing and inflammation resolution[22]. Therefore, the M1/M2 type immune response can be evaluated by the TNF- $\alpha$ /IL-4 ratio and the TNF- $\alpha$ /IL-10 ratio. 227

In this study, by collecting laboratory test results, imaging data, and medical history, we discovered that the levels of various inflammatory factors and immune status in patients with acute cerebral infarction were affected by the infarct size.

The infarct size significantly affects the immune system. While several studies 231 have focused on the effect of infarct size on adaptive immune function impairment, we 232 explored its effects on the immune status and the balance between proinflammatory and 233 anti-inflammatory responses. Fluctuations in various cytokine levels in the peripheral 234 circulation can reflect changes in peripheral immunity following stroke. Our results 235 showed that the levels of cytokines (IFN-γ, TNF-α, IL-2, IL-4, IL-6, IL10, IL-17A) 236 were significantly higher in the group with large-area cerebral infarction than those in 237 non-large-area cerebral infarction group; however, the extent of increase varied for each 238 cytokine. Furthermore, compared to the baseline-matched non-large cerebral infarction 239 group, the absolute value and percentage of lymphocytes decreased significantly in 240 patients with large cerebral infarctions; however, the NLR was significantly higher in 241 the large-area cerebral infarction group. Neutrophils are crucial in innate immunity, and 242

the NLR reflects the degree of immune disorder. A higher NLR indicated a greater 243 degree of adaptive immunity impairment. Our findings suggest that patients with large-244 area cerebral infarctions have more impaired adaptive immune functions, and the 245 relative levels of cytokines affect the immune status (adaptive immunity). Additionally, 246 we calculated the IFN- $\gamma$ /IL-4, TNF- $\alpha$ /IL-4, and TNF- $\alpha$ /IL-10 ratios. The data showed 247 that the TNF- $\alpha$ /IL-4 ratio was significantly decreased in the group with large-area 248 249 cerebral infarction, indicating a more anti-inflammatory balance. Notably, the IFN- $\gamma/IL-4$  and TNF- $\alpha/IL-10$  ratios were decreased, suggesting a shift towards an anti-250 251 inflammatory response in patients with severe infarction.

The immune response is involved throughout cerebral infarction and plays an 252 important role in the process of disease transformation with a great degree of variation. 253 Therefore, it is a potential target for improving the prognosis and outcomes of 254 neurological function. However, at present, there is no systematic research on the 255 effects of the infarct volume on cytokines in patients with acute ischemic stroke.and 256 there is a lack of a deeper understanding of the impact of the immune status on clinical 257 adverse events. Cerebral infarction is a complex disease; several conditions induce it, 258 and the pathological mechanism after its onset is complicated. 259

This study collected first-hand clinical information on patients and systematically analyzed that severity of infarction may affect the serum cytokine levels and immune status of patients with acute cerebral infarction, and explored how it regulates immunity. This study provides valuable clinical data for related fields and enables the clinicians to make informed decisions in selecting immunotherapy approaches and tailor rehabilitation strategies to optimize patient outcomes by considering different infarct sizes.

267

12

268

269

## 270 Acknowledgment

We are highly thankful to Bethune First Hospital of Jilin University, Professor Ms. Wang, and
Professor Ms.Ma for guiding us to finalize this article.Thanks to Xingqi Su, Lingmin Zhao,Jiulin
You,LiangShu Feng,LiChong Zhu,Ying Chen,YuLei Hao,XinYu Wang ,JiaChun Feng,the above
authors for their joint efforts.

275

## 276 Funding

277 None.

278

## 279 Data availability

280 The data that support the findings of this study are available from the corresponding author281 upon reasonable request.

282

## 283 ethics statements

The Ethics Committee of the First Hospital of Jilin University reviewed and approved the study, ensuring that it adhered to ethical principles and guidelines for human subject research. The approval number AF-IRB-032-02 indicates that the study has undergone thorough ethical scrutiny and met the necessary requirements.

288

The participants were provided with detailed information about the study, including its purpose,
 procedures, potential risks and benefits, confidentiality measures, and their rights as participants.
 They were given ample time to ask questions and clarify any concerns before voluntarily signing
 the consent form.

293

The written informed consent form documented the participant's agreement to participate in the study and their understanding of the information provided. It also stated that they could withdraw from the study at any time without penalty.

297

To ensure confidentiality, the consent forms were securely stored and accessible only to the research team. Any identifying information was anonymized or coded to protect the participants' privacy. The research team will continue to prioritize the welfare and rights of the participants throughout the study, maintaining ethical standards and promptly addressing any concerns that may arise.

- Atients with acute ischemic stroke that presented within 72 h of onset from October 2017 to
- 304 October 2019 were enrolled.

#### References 305

- 1.Pan J, Li X, Peng Y. Remote ischemic conditioning for acute ischemic stroke: dawn in the 306
- darkness. Reviews in the Neurosciences. 2016;27. 307
- 2.Fernandez DM, Rahman AH, Fernandez NF, Chudnovskiy A, Giannarelli C. Single-cell immune 308 309 landscape of human atherosclerotic plaques. Nature Medicine. 2019;25(10).
- 310 3.Pakzad B, Rajae E, Shahrabi S, Mansournezhad S, Saki N. T-Cell Molecular Modulation 311 Responses in Atherosclerosis Anergy. Laboratory Medicine. 2020;(16).
- 4.Yi X, Zhu L, Sui G, Li J, Bao S. Inflammation and Endothelial Function Relevant Genetic 312
- Polymorphisms and Carotid Plaque in Chinese Population. Journal of Atherosclerosis and 313 Thrombosis. 2020;27(9). 314
- 5.Korn T, Kallies A. T cell responses in the central nervous system. Nature Reviews Immunology. 315 316 2017;17(3):179-94. doi: 10.1038/nri.2016.144.
- 6.Becker KJ, Kalil AJ, Tanzi P, Zierath DK, Savos AV, Gee JM, et al. Autoimmune responses to 317 the brain after stroke are associated with worse outcome. Stroke. 2011;42(10):2763-9. Epub 318
- 20110728. doi: 10.1161/strokeaha.111.619593. 319
- 320 7.Ren H, Liu X, Wang L, Gao Y. Lymphocyte-to-Monocyte Ratio: A Novel Predictor of the Prognosis of Acute Ischemic Stroke. J Stroke Cerebrovasc Dis. 2017;26(11):2595-321 322 602.Epub20170826.doi:10.1016/j.jstrokecerebrovasdis.2017.06.019.
- 8.Nam KW, Kim TJ, Lee JS, Kwon HM, Lee YS, Ko SB, et al. High Neutrophil-to-Lymphocyte 323 Stroke-Associated Pneumonia. Stroke. 324 Ratio Predicts 2018;49(8):1886-92. doi: 10.1161/strokeaha.118.021228. 325
- 9.Wang Y, Zhang JH, Sheng J, Shao A. Immunoreactive Cells After Cerebral Ischemia. Front 326 Immunol.2019;10:2781.Epub 20191126. doi:10.3389/fimmu.2019.02781. 327
- 328 10.Jian Z, Liu R, Zhu X, Smerin D, Zhong Y, Gu L, et al. The Involvement and Therapy Target of 329 Immune Cells After Ischemic Stroke. Front Immunol. 2019;10:2167. Epub 20190911. doi: 10.3389/fimmu.2019.02167. 330
- 11.Saino O, Taguchi A, Nakagomi T, Nakano-Doi A, Kashiwamura S, Doe N, et al. 331 Immunodeficiency reduces neural stem/progenitor cell apoptosis and enhances neurogenesis in the 332 cerebral cortex after stroke. J Neurosci Res. 2010;88(11):2385-97. doi: 10.1002/jnr.22410. 333
- 334 12. Butovsky O, Ziv Y, Schwartz A, Landa G, Talpalar AE, Pluchino S, et al. Microglia activated 335 by IL-4 or IFN-gamma differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. Mol Cell Neurosci. 2006;31(1):149-60. Epub 20051116. doi: 336 10.1016/j.mcn.2005.10.006. 337
- 13. Albini A, Marchisone C, Del Grosso F, Benelli R, Masiello L, Tacchetti C, et al. Inhibition of 338 angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy 339 approach.Am J Pathol.2000;156(4):1381-93.doi: 10.1016/s0002-9440(10)65007-9. 340
- 341 14. Wang S, Zhang H, Xu Y. Crosstalk between microglia and T cells contributes to brain damage and recovery after ischemic stroke. Neurol Res. 2016;38(6):495-503. Epub 20160531. doi: 342 10.1080/01616412.2016.1188473. 343
- 15.Cramer JV, Benakis C, Liesz A. T cells in the post-ischemic brain: Troopers or paramedics?J 344 Neuroimmunol. 2019;326:33-7. Epub 20181113. doi: 10.1016/j.jneuroim.2018.11.006. 345
- 346 16. Jickling GC, Liu D, Ander BP, Stamova B, Zhan X, Sharp FR. Targeting neutrophils in ischemic
- 347 stroke: translational insights from experimental studies. J Cereb Blood Flow Metab.

**348** 2015;35(6):888-901. Epub 20150325. doi: 10.1038/jcbfm.2015.45.

- 349 17.Maestroni GJ. Sympathetic nervous system influence on the innate immune response. Ann N Y
- **350** Acad Sci. 2006;1069:195-207. doi: 10.1196/annals.1351.017.
- 351 18.Yuan M, Han B, Xia Y, Liu Y, Wang C, Zhang C. Augmentation of peripheral lymphocyte-
- derived cholinergic activity in patients with acute ischemic stroke. BMC Neurol. 2019;19(1):236.
- **353** Epub 20191015. doi: 10.1186/s12883-019-1481-5.
- 19. Prass K, Meisel C, Höflich C, Braun J, Halle E, Wolf T, et al. Stroke-induced immunodeficiency
- 355 promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by
- poststroke T helper cell type 1-like immunostimulation. J Exp Med. 2003;198(5):725-36. Epub
   20030825. doi: 10.1084/jem.20021098.
- 358 20.Sekiya T, Yoshimura A. In Vitro Th Differentiation Protocol. Methods Mol Biol.
   359 2016;1344:183-91. doi: 10.1007/978-1-4939-2966-5 10.
- 360 21.Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F,
- 361 et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol.
- **362** 2018;233(9):6425-40. Epub 20180301. doi: 10.1002/jcp.26429.
- 363 22.Tschoe C, Bushnell CD, Duncan PW, Alexander-Miller MA, Wolfe SQ. Neuroinflammation
- after Intracerebral Hemorrhage and Potential Therapeutic Targets. J Stroke. 2020;22(1):29-46. Epub
- **365** 20200131. doi: 10.5853/jos.2019.02236.
- 366
- 367
- 368
- 369



medRxiv preprint doi: https://doi.org/10.1101/2023.10.16.23297078; this version posted October 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .









medRxiv preprint doi: https://doi.org/10.1101/2023.10.16.23297078; this version posted October 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .





# Fig 1



medRxiv preprint doi: https://doi.org/10.1101/2023.10.16.23297078; this version posted October 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 international license.











